Table 3.
Differences between the groups regarding the participation in the therapy and the experienced side effects
| NM | FGM | SGM/TGM | p-value | |
|---|---|---|---|---|
| Therapy | ||||
| Surgery | 406 (92.5%) | 94 (92.2%) | 55 (91.7%) | 0.97 |
| Chemotherapy | 368 (84.2%) | 87 (82.9%) | 51 (85.0%) | 0.27 |
| Radiotherapy | 130 (30.9%) | 33 (33.7%) | 15 (25.4%) | 0.74 |
| Anti-hormone therapy | 98 (23.4%) | 27 (26.7%) | 17 (29.3%) | 0.64 |
| Immunotherapy | 171 (40.0%) | 28 (29.2%) | 25 (41.7%) | 0.21 |
| Recurrence | 164 (40.3%) | 34 (35.1%) | 29 (50.0%) | 0.24 |
| Therapy side effects | ||||
| Pain | 198 (46.8%) | 54 (52.9%) | 26 (44.8%) | 0.48 |
| Alopecia | 288 (68.1%) | 72 (70.6%) | 42 (72.4%) | 0.74 |
| Fatigue | 253 (59.8%) | 67 (65.7%) | 41 (70.7%) | 0.19 |
| Blood changes | 220 (52.0%) | 42 (41.2%) | 34 (58.6%) | 0.06 |
| Cardiac function changes | 16 (3.8%) | 9 (8.8%) | 1 (1.7%) | 0.05 |
| Nausea | 158 (37.4%) | 50 (49.0%) | 31 (53.4%) | 0.01 |
| Paresthesia | 240 (56.7%) | 56 (54.9%) | 36 (62.1%) | 0.67 |